Skip to main content

Vericel Value Stock - Dividend - Research Selection

Vericel

ISIN: US92346J1088, WKN: A12FU4

Market price date: 22.01.2021
Market price: 41,23 USD




Vericel Fundamental data and company key figures of the share

Annual reports in USD
Key figures 28-02-2020
Cash flow
Net operating cash flow -7.183.000
Capital Expenditures 7.183.000
Free cash flow -14.366.000
Balance sheet
Total Equity 111.091.000
Liabilities & Shareholders equity 153.238.000
Income statement
Net income -9.665.000
Eps (diluted) -0,220
Diluted shares outstanding 43.931.800
Net sales/revenue 117.850.000

Fundamental ratios calculated on: 22-01-2021

Ratios
Key figures 22-01-2021
Cash flow
P/C -252,17
   
P/FC -126,08
Balance sheet
ROI-6,31
ROE72,50
Income statement
P/E-187,41
Div. Yield0,00%
P/B16,31
P/S15,37


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
SymbolVCEL
Market Capitalization1.763.861.760,00 USD
CountryUnited States
IndicesNASDAQ Comp.
SectorsBiotechnology
Raw Data SourceUS GAAP in Millionen USD
Stock Split2013-10-16,1.0000/20.0000; 2010-02-18,1.0000/8.0000
Internetwww.vcel.com


Description of the company

Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, markets, and sells patient-specific expanded cellular therapies to repair and regenerate damaged tissues and organs. It markets autologous cell therapy products, including MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Carticel, an autologous chondrocyte implant for the repair of symptomatic cartilage defects of the femoral condyle caused by acute or repetitive trauma in patients that have inadequate response to a prior arthroscopic or other surgical repair procedure. The company also markets Epicel, a permanent skin replacement humanitarian use device for the treatment of patients with deep-dermal or full-thickness burns. In addition, it develops ixmyelocel-T, a patient-specific multicellular therapy that has completed Phase IIb clinical trial for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was founded in 1989 and is headquartered in Cambridge, Massachusetts.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov, www.vcel.com